CVTX trending down despite good news

CV Therapeutics is again trading under 9. The stock has been battered by continued slow growth of the sales of Ranexa, their lead compound.

I continue to believe CVTX is attractive. The route to commercial success seems even more clear today. Since I last wrote about the stock, the company has presented and published data from their recent trial- which showed that the drug actually prevents ventricular arrythmias- dangerous heart rhythms that the FDA was concerned the drug might cause. It also decreased atrial fibrillation. This has resulted in very favorable coverage from influential sites like theheart.org. On Thursday the company announced that they have submitted an SNDA to the FDA- this is an application to change the language on the drugs label to make it first line for angina and remove a great deal of verbage regarding arrythmias. When this was announce the stock traded up 3% in the after hours only to actually end down 3% on the news the next day. The reason for that move is puzzling to me.

The company will probably be presenting the Diabetes data from their main trial in about 1 month at the AHA. They have stated that this data was favorable, and if it is as favorable as I suspect it will be the stock should trade much higher than it is now.

So, in about 9- 10 months, this drug will be much easier to sell than it is now- and if the diabetes data comes through, there will be a large pharma company selling it to primary care doctors for a piece of the action.

All of this makes this a very attractive entry point for the stock.